Zhulai T. The experimental substantiation of Enisamium iodide application in topical therapy of acute rhinosinusitis

The thesis is devoted to substantiating the practicability of using a known medicine with multitype pharmacodynamics Enisamium iodide in a new dosage form  a nasal spray to optimize the topical therapy of acute rhinosinusitis to according with the appropriate medicine concept. According to the study results, it has been proven that Enisamium Iodide (nasal spray) 10 mg/mL is a low-toxic substance when administered intranasally and intragastrically (toxicity class IV). Enisamium Iodide 10 mg/mL (nasal spray) in the single-dose instillation into the rabbit eye conjunctival sacs and rabbit nasal passage did not show local drug-induced irritant effect and lead to olfactory dysfunction. According to the Enisamium Iodide (nasal spray) screening study results, the most effective concentration for anti-inflammatory and analgesic properties is 10 mg/mL (р<0.05): 5 мг/мл (14.5% та 20.6%, respectively) < 10 мг/мл (35.3% та 43.4%, respectively) > 20 мг/мл (22.5% та 33.5%, respectively). It is this concentration has been chosen for further studies. With an in-depth study of Enisamium Iodide (nasal spray) 10 mg/mL pharmacological profile, it has been proved that Enisamium Iodide was shown pronounced anti-inflammatory properties; these differences are significant compared to the reference drug ibuprofen with exceeding its activity on 30 minutes (18.6%). It has been confirmed that Enisamium iodide has pronounced analgesic properties, these differences are significant compared to the reference drug ibuprofen with exceeding its activity on 30 minutes and the first hour (30.9% and 23.7%, respectively) (р<0.05). Such pharmacodynamic features can be explained by an effect on the leukotriene pathway of the inflammatory process, which will be manifested by a higher rate of the clinical effect development. It has been found that Enisamium iodide (nasal spray) 10 mg/mL has a significantly high antialterative activity  on average for the entire observation period antialterative activity was 27.56% compared with ibuprofen 18.6% and moderate antiproliferative activity without tendentious differences (14.24% and 15.05%, respectively). Summarizing the obtained results, it is possible to conclude that EISN10 mg/mL is a promising medicine with polyvalent pharmacodynamics for further preclinical and clinical studies to expand the of native drugs' range for appropriate medicine of ARS treatment and its optimization.